Sambucus racemosa

Sambucus racemosa, red elderberry, contains lectins and cyanogenic glycosides as primary bioactive compounds that interact with toll-like receptor 4 (TLR4) signaling pathways to modulate innate immune responses. Preliminary in vitro evidence suggests these compounds activate JNK-mediated macrophage activity, though clinical human data remain limited.

Origin & History

Sambucus racemosa, commonly known as red elderberry or racemose elder, is a deciduous shrub native to temperate regions of the Northern Hemisphere. The plant's leaves, berries, and flowers are used medicinally, with aqueous extracts being the primary preparation form studied, yielding immunostimulatory preparations containing polyphenolic compounds and flavonoids.

Historical & Cultural Context

While specific traditional use documentation for Sambucus racemosa is limited in available sources, related Sambucus species, particularly S. ebulus (dwarf elder), have been traditionally used to treat inflammatory conditions including sore throat, joint pains, and rheumatic pains. S. nigra has a long history in European folk medicine for respiratory and immune support.

Health Benefits

• Immune system stimulation through TLR4-dependent JNK activation in macrophage cells (preliminary evidence from in vitro studies)
• Enhanced phagocytic activity in immune cells, potentially supporting natural defense mechanisms (demonstrated in cell culture models)
• Potential respiratory support based on related species data showing 50% symptom reduction within 2-4 days (strong evidence for S. nigra, not S. racemosa)
• Anti-inflammatory activity through modulation of inflammatory mediators including TNF-α and IL-1β (preliminary evidence from cell studies)
• Traditional use for inflammatory conditions, though specific clinical evidence for S. racemosa is lacking

How It Works

Sambucus racemosa extracts interact with toll-like receptor 4 (TLR4) on macrophages, triggering downstream c-Jun N-terminal kinase (JNK) phosphorylation that upregulates pro-inflammatory cytokine production including TNF-α and IL-6. The lectin constituents are believed to enhance phagocytic activity by stimulating F-actin polymerization in immune cells, improving pathogen engulfment efficiency. Cyanogenic glycosides such as sambunigrin undergo enzymatic hydrolysis to release hydrogen cyanide at low concentrations, which may contribute to both antimicrobial and potentially toxic properties depending on preparation method.

Scientific Research

Direct clinical evidence for Sambucus racemosa is currently limited to in vitro mechanistic studies in macrophage cell cultures. However, related Sambucus nigra has robust clinical support, including a meta-analysis of 180 participants showing substantial reduction in upper respiratory symptoms with large effect sizes, and a rapid review of five clinical studies (936 adults) demonstrating approximately 50% symptom reduction within 2-4 days when taken within 48 hours of symptom onset.

Clinical Summary

Current evidence for Sambucus racemosa is largely confined to in vitro cell culture models and animal studies, with no robust randomized controlled trials in human populations established as of the latest review. Cell-based studies have demonstrated measurable increases in phagocytic index in macrophage cultures exposed to standardized aqueous extracts, but sample conditions do not reliably translate to oral bioavailability in humans. German Commission E has not approved Sambucus racemosa for any therapeutic indication, distinguishing it from its close relative Sambucus nigra, which carries more documented human study data. The overall evidence strength is preliminary, and quantified clinical outcomes such as infection rate reduction or immune marker improvement in humans are not yet available.

Nutritional Profile

Sambucus racemosa (red elderberry) berries contain moderate levels of vitamin C (approximately 36-40 mg per 100g fresh weight, though lower than S. nigra), with small amounts of vitamin A precursors (beta-carotene estimated at 300-400 µg/100g). Carbohydrate content is approximately 11-13g/100g, predominantly fructose and glucose, with dietary fiber around 7g/100g including pectin fractions. Protein content is low at approximately 0.7-1.0g/100g. Fat content is negligible at under 0.5g/100g, though seeds contain fatty acids including linoleic acid. Key bioactive compounds include cyanogenic glycosides (sambunigrin, primarily in unripe berries and seeds, requiring heat processing to reduce to safe levels), anthocyanins predominantly cyanidin-3-sambubioside and cyanidin-3-glucoside (estimated 200-400 mg/100g, notably lower concentration than S. nigra). Flavonoids include quercetin, rutin, and kaempferol derivatives (combined approximately 50-150 mg/100g). Triterpene acids including alpha- and beta-amyrin, ursolic acid, and oleanolic acid are present in bark and leaves. Lectins (SRL, Sambucus racemosa lectin) are documented bioactive proteins with demonstrated hemagglutinating activity. Mineral content includes potassium (~280 mg/100g), calcium (~38 mg/100g), phosphorus (~39 mg/100g), and iron (~1.6 mg/100g). Bioavailability of anthocyanins is limited (typically 1-5% absorption), though the polyphenol matrix may enhance local gastrointestinal effects. Data on specific micronutrient concentrations is more limited compared to S. nigra, with most precise analytical work conducted on European populations of the species.

Preparation & Dosage

In vitro studies of Sambucus racemosa aqueous extract employed concentrations of 12.5-50 µg/ml in cell culture systems. However, equivalent human oral dosing recommendations cannot be reliably extrapolated from these laboratory concentrations without clinical pharmacokinetic data. No standardized human dosage recommendations are available in the current literature. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Echinacea purpurea, Astragalus membranaceus, Vitamin C, Zinc, Vitamin D3

Safety & Interactions

Raw or unripe Sambucus racemosa berries, bark, leaves, and roots contain significant concentrations of cyanogenic glycosides including sambunigrin and prunasin, which can cause nausea, vomiting, and diarrhea upon ingestion of unprocessed material. Proper cooking or processing degrades these glycosides substantially, reducing acute toxicity risk, but standardized safe processing thresholds for commercial preparations have not been formally established. Individuals taking immunosuppressant medications such as cyclosporine or corticosteroids should exercise caution, as the immune-stimulating lectins may theoretically counteract drug effects, though direct interaction studies are absent. Use during pregnancy and breastfeeding is not recommended due to insufficient safety data and the known presence of cyanogenic compounds in the raw plant.